Latest research on solifenacin succinate

Solifenacin (rINN), marketed as solifenacin succinate under the trade name Vesicare, is a urinary antispasmodic of the anticholinergic class. It is used in the treatment of overactive bladder with urge incontinence. [Wikipedia]

Latest findings

A new-generation antimuscarinic agent, solifenacin succinate (Vesicare®; Astellas Pharma Co. Ltd, Tokyo, Japan), is a once-daily oral agent that shows apparent functional selectivity for the bladder over other organs in animal models (6). [source, 2008]
solifenacin succinate is a once-daily, oral antimusarinic agent, which shows in vitro selectivity for bladder tissue over salivary preparations (7,8). [source, 2006]